Displaying 13 - 24 of 32
Immune-Mediated and Cholestatic Diseases
4

AdvanzPharma: Shifting Paradigms in PBC Management - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
4

AdvanzPharma: Shifting Paradigms in PBC Management - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
4

AdvanzPharma: Shifting Paradigms in PBC Management - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
5

Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022

View
Metabolism, Alcohol & Toxicity
5

Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022

View
Metabolism, Alcohol & Toxicity
5

Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022

View
Metabolism, Alcohol & Toxicity
5

Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022

View
Liver Tumours
5

Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022

View
Liver Tumours
5

Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022

View
Liver Tumours
5

Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022

View
Liver Tumours
5

Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022

View
Liver Tumours
5

Boston Scientific: Radioembolisation in the BCLC and beyond: An MDT approach - Liver Cancer Summit 2022

View
Displaying 13 - 24 of 32